Comparison of Four Treatment Regimens as First-Line Therapy for Helicobacter pylori Infection in Chinese Children Including Resistance and Impact Factor Studies in a Multicenter Trial

What this Trial Is About

Researchers are evaluating four different treatment plans as the first choice for Helicobacter pylori infection in Chinese children aged 6 to 18 years. This study addresses the challenge of increasing resistance to standard treatments and aims to find the most effective regimen among triple therapy, sequential therapy, bismuth quadruple therapy, and concomitant therapy. The study also investigates factors influencing resistance and how these treatments affect the balance of bacteria in the gut. Children who qualify for the study are randomly assigned to one of four treatment groups. The triple therapy group receives Omeprazole, Amoxicillin, and Clarithromycin for 14 days. The sequential therapy group takes Omeprazole and Amoxicillin for the first 7 days, then Omeprazole, Clarithromycin, and Metronidazole for the last 7 days. The bismuth quadruple therapy group is treated with Omeprazole, Amoxicillin, Metronidazole, and Colloidal Bismuth Subcitrate for 14 days. The concomitant therapy group receives Omeprazole, Amoxicillin, Clarithromycin, and Metronidazole together for 14 days. During the study, researchers check if the infection is cleared 4 to 6 weeks after treatment using a breath test called 13C-UBT. They also monitor side effects, factors that might affect treatment success, and changes in the gut microbiome. The results will help develop guidelines for diagnosing and treating Helicobacter pylori in Chinese children, aiming to improve cure rates and reduce antibiotic resistance.

A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children